【摘要】 目的 探究布地奈德福莫特罗对肺癌合并慢性阻塞性肺疾病患者肺功能及生活质量的影响。方法将80例肺癌合并慢性阻塞性肺疾病患者根据治疗方法不同分为观察组（n=40）及对照组（n=40）。对照组进行常规治疗，观察组在对照组基础上进行布地奈德福莫特罗治疗。比较两组患者炎性因子水平、肺功能指标、生活质量及不良反应。结果 治疗后，两组患者白细胞介素-6(IL-6)、C反应蛋白（CRP）、肿瘤坏死因子-α(TNF-α)水平均降低，且观察组患者IL-6、CRP、TNF-α水平均低于对照组，差异均有统计学意义（P﹤0.05）。治疗后，两组患者第1秒用力呼气容积（FEV1）、用力肺活量（FVC）及FEV1/FVC水平均升高，且观察组患者FEV1、FVC及FEV1/FVC水平均高于对照组，差异均有统计意义（P﹤0.05）。治疗后，两组患者活动受限、呼吸症状、疾病影响评分及总分均降低，且观察组患者活动受限、呼吸症状、疾病影响评分及总分均低于对照组，差异均有统计学意义（P﹤0.05）。两组患者不良反应总发生率比较，差异无统计学意义（P﹥0.05）。结论 肺癌合并慢性阻塞性肺疾病患者采用布地奈德福莫特罗治疗可有效降低炎性因子水平，改善肺功能指标，促进生活质量进一步提升，安全性较高。更多还原

【Abstract】 Objective To investigate the effect of budesonide formoterol on lung function and quality of life in patients with lung cancer complicated with chronic obstructive pulmonary disease(COPD). Method A total of 80 patients with lung cancer combined with COPD were divided into the observation group(n=40) and the control group(n=40) according to different treatment methods. The control group was given routine treatment, and the observation group was given budesonide formoterol treatment on the basis of the control group’s regimen. The levels of inflammatory factors, pulmonary function indexes, quality of life and adverse events were compared between the two groups. Result After the treatment, the levels of interleukin-6(IL-6), C-reactive protein(CRP), and tumor necrosis factor-α(TNF-α) in both groups were decreased, the levels of IL-6, CRP and TNF-α in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the levels of forced expiratory volume in one second(FEV1), forced vital capacity(FVC) and FEV1/FVC in both groups were increased, the levels of FEV1,FVC and FEV1/FVC in the observation group were higher than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the activity limitation, respiratory symptoms, disease impact score and total score of patients in the two groups were decreased, and these scores of patients in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse events between the two groups(P>0.05). Conclusion Budesonide formoterol treatment in patients with lung cancer complicated with COPD could effectively reduce patients’ inflammatory factors, improve their pulmonary function indicators, and quality of life, with high safety.更多还原